OBJECTIVES: To describe outcomes associated with high-dose radiotherapy with and without temozolomide for high grade central nervous system (CNS) neoplasms. METHODS: Retrospective chart review of 60 patients diagnosed with malignant glioma treated with > or =70 Gy radiotherapy. RESULTS: Median age at diagnosis was 52 years, and 52 patients had astrocytomas (38 glioblastomas). Median prescribed radiotherapy dose was 78 Gy (range 70-80), and 29 patients received concurrent temozolomide. Eighty-six percent completed the planned course treatment. Three patients experienced RTOG grade 3 acute CNS toxicity; late brain necrosis was suspected in four patients. Overall median survival was 13 months (range 2-83). Within glioblastoma patients, temozolomide provided a statistically significant survival improvement over no chemotherapy (median survival 12.7 vs. 7.5 months; P = 0.0058). CONCLUSIONS: High dose conformal radiotherapy to > or =70 Gy with chemotherapy for high-grade CNS neoplasms appears safe but survival remains suboptimal. Within glioblastoma patients, temozolomide provided statistically significant survival improvement over no chemotherapy.
OBJECTIVES: To describe outcomes associated with high-dose radiotherapy with and without temozolomide for high grade central nervous system (CNS) neoplasms. METHODS: Retrospective chart review of 60 patients diagnosed with malignant glioma treated with > or =70 Gy radiotherapy. RESULTS: Median age at diagnosis was 52 years, and 52 patients had astrocytomas (38 glioblastomas). Median prescribed radiotherapy dose was 78 Gy (range 70-80), and 29 patients received concurrent temozolomide. Eighty-six percent completed the planned course treatment. Three patients experienced RTOG grade 3 acute CNS toxicity; late brain necrosis was suspected in four patients. Overall median survival was 13 months (range 2-83). Within glioblastomapatients, temozolomide provided a statistically significant survival improvement over no chemotherapy (median survival 12.7 vs. 7.5 months; P = 0.0058). CONCLUSIONS: High dose conformal radiotherapy to > or =70 Gy with chemotherapy for high-grade CNS neoplasms appears safe but survival remains suboptimal. Within glioblastomapatients, temozolomide provided statistically significant survival improvement over no chemotherapy.
Authors: K Nakagawa; Y Aoki; T Fujimaki; M Tago; A Terahara; K Karasawa; K Sakata; Y Sasaki; M Matsutani; A Akanuma Journal: Int J Radiat Oncol Biol Phys Date: 1998-03-15 Impact factor: 7.038
Authors: June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler Journal: J Clin Oncol Date: 2002-03-15 Impact factor: 44.544
Authors: Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: M D Walker; E Alexander; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; H A Norrell; G Owens; J Ransohoff; C B Wilson; E A Gehan; T A Strike Journal: J Neurosurg Date: 1978-09 Impact factor: 5.115
Authors: J R Simpson; J Horton; C Scott; W J Curran; P Rubin; J Fischbach; S Isaacson; M Rotman; S O Asbell; J S Nelson Journal: Int J Radiat Oncol Biol Phys Date: 1993-05-20 Impact factor: 7.038
Authors: C H Chang; J Horton; D Schoenfeld; O Salazer; R Perez-Tamayo; S Kramer; A Weinstein; J S Nelson; Y Tsukada Journal: Cancer Date: 1983-09-15 Impact factor: 6.860
Authors: Adam J Esbenshade; Mehmet Kocak; Linda Hershon; Pierre Rousseau; Jean-Claude Decarie; Susan Shaw; Peter Burger; Henry S Friedman; Amar Gajjar; Albert Moghrabi Journal: Pediatr Blood Cancer Date: 2016-12-21 Impact factor: 3.167